[{"id":"c459c21e-279b-40e7-a0c3-b69256f31293","acronym":"","url":"https://clinicaltrials.gov/study/NCT04143711","created_at":"2021-01-18T20:13:28.416Z","updated_at":"2024-07-02T16:35:21.935Z","phase":"Phase 1/2","brief_title":"Study of DF1001 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04143711","lead_sponsor":"Dragonfly Therapeutics","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" HER-2 positive • EGFR mutation • HR positive • HER-2 mutation • HER-2 expression • RET mutation","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • EGFR mutation • HR positive • HER-2 mutation • HER-2 expression • RET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • albumin-bound paclitaxel • Trodelvy (sacituzumab govitecan-hziy) • DF1001"],"overall_status":"Recruiting","enrollment":" Enrollment 378","initiation":"Initiation: 11/11/2019","start_date":" 11/11/2019","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-01-29"}]